GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Liquidia Corp (FRA:LT4) » Definitions » Cash Receipts from Deposits by Banks and Customers

Liquidia (FRA:LT4) Cash Receipts from Deposits by Banks and Customers


View and export this data going back to 2020. Start your Free Trial

What is Liquidia Cash Receipts from Deposits by Banks and Customers?

Cash Receipts from Deposits by Banks and Customers only applicable to companies reporting Cash Flow from Operations in direct method.


Liquidia Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Liquidia Corp (FRA:LT4) » Definitions » Cash Receipts from Deposits by Banks and Customers
Traded in Other Exchanges
Address
419 Davis Drive, Suite 100, Morrisville, NC, USA, 27560
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.